Abstract
High-grade serous ovarian carcinomas (HGSOCs) with BRCA1/2 mutations exhibit improved outcome and sensitivity to double-strand DNA break (DSB)-inducing agents (i.e., platinum and poly(ADP-ribose) polymerase inhibitors [PARPis]) due to an underlying defect in homologous recombination (HR). However, resistance to platinum and PARPis represents a significant barrier to the long-term survival of these patients. Although BRCA1/2-reversion mutations are a clinically validated resistance mechanism, they account for less than half of platinum-resistant BRCA1/2-mutated HGSOCs. We uncover a resistance mechanism by which a microRNA, miR-622, induces resistance to PARPis and platinum in BRCA1 mutant HGSOCs by targeting the Ku complex and restoring HR-mediated DSB repair. Physiologically, miR-622 inversely correlates with Ku expression during the cell cycle, suppressing non-homologous end-joining and facilitating HR-mediated DSB repair in S phase. Importantly, high expression of miR-622 in BRCA1-deficient HGSOCs is associated with worse outcome after platinum chemotherapy, indicating microRNA-mediated resistance through HR rescue.
Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, Non-P.H.S.
MeSH terms
-
Animals
-
Antigens, Nuclear / genetics
-
Antigens, Nuclear / metabolism
-
Antineoplastic Agents / pharmacology*
-
BRCA1 Protein / genetics
-
BRCA1 Protein / metabolism*
-
Base Sequence
-
Cell Line, Tumor
-
DNA End-Joining Repair / drug effects
-
DNA-Binding Proteins / antagonists & inhibitors
-
DNA-Binding Proteins / genetics
-
DNA-Binding Proteins / metabolism
-
Disease-Free Survival
-
Female
-
Homologous Recombination / drug effects
-
Humans
-
Intracellular Signaling Peptides and Proteins / genetics
-
Intracellular Signaling Peptides and Proteins / metabolism
-
Ku Autoantigen
-
Mice
-
MicroRNAs / antagonists & inhibitors
-
MicroRNAs / genetics
-
MicroRNAs / metabolism*
-
Oligonucleotides, Antisense / metabolism
-
Organoplatinum Compounds / pharmacology*
-
Ovarian Neoplasms / genetics
-
Ovarian Neoplasms / mortality
-
Ovarian Neoplasms / pathology
-
Poly(ADP-ribose) Polymerase Inhibitors / pharmacology*
-
RNA Interference
-
Sequence Alignment
-
Tumor Suppressor p53-Binding Protein 1
Substances
-
Antigens, Nuclear
-
Antineoplastic Agents
-
BRCA1 Protein
-
DNA-Binding Proteins
-
Intracellular Signaling Peptides and Proteins
-
MicroRNAs
-
Oligonucleotides, Antisense
-
Organoplatinum Compounds
-
Poly(ADP-ribose) Polymerase Inhibitors
-
TP53BP1 protein, human
-
Tumor Suppressor p53-Binding Protein 1
-
Xrcc6 protein, human
-
Xrcc6 protein, mouse
-
Ku Autoantigen